• By ICR Secretariat
  • Posted Tuesday, November 29, 2022

Infex begins study of pseudomonas aeruginosa candidate RESP-X


Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers

Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.